PE20010050A1 - Dihidrato de hidrocloruro de 5-[4-[2-n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona - Google Patents

Dihidrato de hidrocloruro de 5-[4-[2-n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona

Info

Publication number
PE20010050A1
PE20010050A1 PE2000000361A PE0003612000A PE20010050A1 PE 20010050 A1 PE20010050 A1 PE 20010050A1 PE 2000000361 A PE2000000361 A PE 2000000361A PE 0003612000 A PE0003612000 A PE 0003612000A PE 20010050 A1 PE20010050 A1 PE 20010050A1
Authority
PE
Peru
Prior art keywords
diona
benzyl
pyridyl
methyl
amino
Prior art date
Application number
PE2000000361A
Other languages
English (en)
Inventor
Robert Gordon Giles
Michael John Sasse
Paul David James Blackler
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of PE20010050A1 publication Critical patent/PE20010050A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SE REFIERE AL DIHIDRATO DE HIDROCLORURO DE 5-[4-[2-N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]BENCIL]TIAZOLIDINA-2,4-DIONA CARACTERIZADO POR: a)UN ESPECTRO INFRARROJO; b) UN ESPECTRO DE DIFRACCION DE RAYOS X; SE PUEDE PRESENTAR EN FORMA PURA, AISLADA, CRISTALINA. SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA PREPARACION CARACTERIZADO PORQUE LA 5-[4-[2-N-METIL-N-(2-PIRIDIL)AMINO)ETOXI]BENCIL]TIAZOLIDINA-2,4-DIONA SE TRATA CON UNA FUENTE DE IONES CONTRARIOS DE HIDROCLORURO Y UNA CANTIDAD APROPIADA DE AGUA PARA QUE SE FORME EL HIDRATO DE HIDROCLORURO Y DESPUES DE ELLO SE RECUPERA EL COMPUESTO REQUERIDO. EL HIDRATO DE HIDROCLORURO DE 5-[4-[2-N-METIL-(2-PIRIDIL AMINO)ETOXI]BENCIL]TIAZOLIDINA-2,4-DIONA ES UTIL PARA EL TRATAMIENTO DE DIABETES MELLITUS Y COMPLICACIONES DE LA MISMA
PE2000000361A 1999-04-20 2000-04-18 Dihidrato de hidrocloruro de 5-[4-[2-n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona PE20010050A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9909041.7A GB9909041D0 (en) 1999-04-20 1999-04-20 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
PE20010050A1 true PE20010050A1 (es) 2001-03-10

Family

ID=10851901

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000361A PE20010050A1 (es) 1999-04-20 2000-04-18 Dihidrato de hidrocloruro de 5-[4-[2-n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona

Country Status (42)

Country Link
EP (2) EP1173436B1 (es)
JP (2) JP4283449B2 (es)
KR (1) KR100601244B1 (es)
CN (2) CN1327447A (es)
AP (1) AP1562A (es)
AR (2) AR023566A1 (es)
AT (1) ATE268770T1 (es)
AU (2) AU4130900A (es)
BG (1) BG65864B1 (es)
BR (1) BR0009897A (es)
CA (1) CA2382036A1 (es)
CO (1) CO5170422A1 (es)
CZ (1) CZ300653B6 (es)
DE (1) DE60011419T2 (es)
DK (1) DK1173436T3 (es)
DZ (1) DZ3162A1 (es)
EA (1) EA004232B1 (es)
EG (1) EG24063A (es)
ES (1) ES2218146T3 (es)
GB (1) GB9909041D0 (es)
HK (1) HK1045151B (es)
HR (1) HRP20010770B1 (es)
HU (1) HUP0200865A3 (es)
IL (1) IL146078A0 (es)
MA (1) MA26783A1 (es)
MX (1) MXPA01010696A (es)
MY (1) MY126034A (es)
NO (1) NO320609B1 (es)
NZ (1) NZ515166A (es)
OA (1) OA11866A (es)
PE (1) PE20010050A1 (es)
PL (1) PL351135A1 (es)
PT (1) PT1173436E (es)
RS (1) RS50136B (es)
SI (1) SI1173436T1 (es)
SK (1) SK284991B6 (es)
TR (1) TR200103040T2 (es)
TW (1) TWI277616B (es)
UA (1) UA71615C2 (es)
UY (1) UY26112A1 (es)
WO (1) WO2000063205A2 (es)
ZA (1) ZA200108720B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
EP1448559B1 (en) * 2001-11-21 2006-12-27 Smithkline Beecham Plc 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
CZ296468B6 (cs) * 2004-06-10 2006-03-15 Zentiva, A. S. Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
CZ296472B6 (cs) * 2004-07-27 2006-03-15 Zentiva, A. S Sul kyseliny stavelové s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionu azpusob její prípravy a její pouzití
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
EP1842850A1 (en) * 2006-03-23 2007-10-10 Sandoz AG Rosiglitazone hydrochloride hemihydrate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
GB9726563D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726568D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726566D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical

Also Published As

Publication number Publication date
PT1173436E (pt) 2004-10-29
HUP0200865A2 (en) 2002-08-28
CZ300653B6 (cs) 2009-07-08
EG24063A (en) 2008-05-08
BG65864B1 (bg) 2010-03-31
HUP0200865A3 (en) 2005-04-28
EA004232B1 (ru) 2004-02-26
ZA200108720B (en) 2002-11-28
DZ3162A1 (fr) 2000-10-26
RS50136B (sr) 2009-03-25
AP2001002331A0 (en) 2000-04-19
AR023562A1 (es) 2002-09-04
WO2000063205A3 (en) 2001-01-25
HRP20010770B1 (en) 2005-06-30
MY126034A (en) 2006-09-29
NO20015104D0 (no) 2001-10-19
MA26783A1 (fr) 2004-12-20
KR20010110791A (ko) 2001-12-13
JP4283449B2 (ja) 2009-06-24
JP2002542242A (ja) 2002-12-10
EP1173436A2 (en) 2002-01-23
EP1173436B1 (en) 2004-06-09
JP2009143954A (ja) 2009-07-02
ES2218146T3 (es) 2004-11-16
NO20015104L (no) 2001-12-19
AU2755202A (en) 2002-05-16
HK1045151A1 (en) 2002-11-15
PL351135A1 (en) 2003-03-24
DK1173436T3 (da) 2004-09-27
SK284991B6 (sk) 2006-04-06
CO5170422A1 (es) 2002-06-27
AU765911B2 (en) 2003-10-02
NO320609B1 (no) 2005-12-27
CN1327447A (zh) 2001-12-19
EA200101101A1 (ru) 2002-04-25
HK1045151B (zh) 2005-03-18
EP1411055A1 (en) 2004-04-21
ATE268770T1 (de) 2004-06-15
AP1562A (en) 2006-02-01
GB9909041D0 (en) 1999-06-16
UA71615C2 (uk) 2004-12-15
IL146078A0 (en) 2002-07-25
YU81501A (sh) 2004-07-15
TWI277616B (en) 2007-04-01
BR0009897A (pt) 2002-04-16
HRP20010770A2 (en) 2002-10-31
TR200103040T2 (tr) 2002-04-22
AR023566A1 (es) 2002-09-04
CA2382036A1 (en) 2000-10-26
WO2000063205A2 (en) 2000-10-26
SI1173436T1 (en) 2004-12-31
CN101134756A (zh) 2008-03-05
NZ515166A (en) 2004-02-27
AU4130900A (en) 2000-11-02
MXPA01010696A (es) 2002-06-04
BG106112A (bg) 2002-05-31
UY26112A1 (es) 2000-12-29
KR100601244B1 (ko) 2006-07-19
OA11866A (en) 2006-03-02
CZ20013759A3 (cs) 2002-05-15
DE60011419T2 (de) 2005-06-16
DE60011419D1 (de) 2004-07-15
SK14902001A3 (sk) 2002-02-05

Similar Documents

Publication Publication Date Title
UY25309A1 (es) Procedimiento para la preparación de un hidrato de un derivado de tiazolidin-2,4-diona
PE20010050A1 (es) Dihidrato de hidrocloruro de 5-[4-[2-n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona
AR057970A2 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
JP2002508371A5 (es)
MY129897A (en) Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
JO2239B1 (en) Method for preparing benzothophen derivatives
NZ515163A (en) Thiazolidinedione derivative and its use as antidiabetic
UY25308A1 (es) Procedimiento para la preparación de un hidrato de un derivado de tiazolidin-2,4-diona.
PE20010047A1 (es) Monohidrato de hidrocloruro de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
JP2002508372A5 (es)
PE20000057A1 (es) Hidrato de la sal del acido maleico de la 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona
PE20010045A1 (es) Polimorfo de sal del acido maleico de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]-tiazolidin-2,4-diona
AR016660A1 (es) Procedimiento para preparar 5-{4-[2-(n-metil-n(2-piridil)amino)etoxi]bencil} -2,4-tiazolidindiona, o una de sus formas tautomericas o de sus sales
UY25032A1 (es) Procedimiento para preparar una nueva composicion
MY129475A (en) Process for the preparation of substituted thiazolidinedione
AP1600A (en) Combination of a thiazolidinedione and a sulphonylurea for treating diabetes
NZ501256A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
AU2001284285A1 (en) A thiazolidinedione derivative and its use as antidiabetic
NZ524933A (en) Sodium salts of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical composition thereof
AU2001284274A1 (en) A thiazolidinedione derivative and its use as antidiabetic
MXPA02012100A (es) Sal de tiazodilindiona para el tratamiento de la diabetes mellitus.
DK1446404T3 (da) Rosiglitazonedisylater og deres anvendelse som antidiabetika
NO20075507L (no) Tiazolidindionderivater og deres anvendelse som antidiabetiske midler
ATE488515T1 (de) Rosiglitazonhydrochlorid-hemihydrat

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed